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Abstract
Lupus nephritis (LN) is an important cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE) often
leading to end-stage renal failure (ESRF) and necessitating renal transplantation (rTp). Optimal timing of rTp in SLE patients
with ESRF is uncertain and could potentially affect survival. We investigated the time spent on dialysis before rTp and survival
following rTp in a cohort of SLE patients. Retrospective analysis of all adult SLE patients receiving rTp over a 40-year period
(1975–2015) in two tertiary UK centres. Cox proportional hazard regression and receiver operator curves (ROC) were used to
determine the risk associated with time on dialysis before rTp and other potential predictors. Forty patients (age 35 ± 11 years, 34
female, 15 Caucasian, 15 Afro–Caribbean and 10 South Asian) underwent rTp. During a median follow-up of 104 months (IQR
80,145), eight (20%) patients died and the 5-year survival was 95%. Univariate analysis identified time on dialysis prior to rTp as
the only potentially modifiable risk predictor of survival with a hazard ratio of 1.013 for each additional month spent on dialysis
(95% CI = 1.001–1.026, p = 0.03). ROC curves demonstrated that > 24 months on dialysis had an adverse effect with sensitivity
of 0.875 and specificity 0.500 for death. No other modifiable predictors were significantly associated with mortality, indicating
that time on dialysis had an independent effect. Increased time on dialysis pre-transplantation is an independent modifiable risk
factor of mortality in this cohort of patients with lupus nephritis.
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Introduction
Systemic lupus erythematosus (SLE) is a heterogenous auto-
immune rheumatic disease with particularly high prevalence
in women of childbearing age [1]. The kidneys are often af-
fected, with at least one-third of SLE patients developing overt
renal disease, while 10–25%may reach end-stage renal failure
(ESRF) requiring dialysis or kidney transplantation and 10–
20% of patients die within 10 years [2]. Lupus nephritis (LN)
remains one of the most common and severe manifestations of
SLE. There are racial, ethnic and regional variations in the
incidence, prevalence and prognosis of LN [3]. Specifically
younger age (< 33 years), non-European ancestry and male
gender (in some but not all series) were found to associate
with earlier development of renal disease. Moreover,
African–Caribbean, African–American and South Asian eth-
nicities usually have worse renal involvement when compared
to other ethnic groups. Furthermore, Black and Hispanic pa-
tients with LN tend to have poorer prognosis and a higher risk
of renal disease and mortality [4].
In those patients reaching ESRF, renal transplantation (rTp)
has now become an accepted and preferred treatment.
However, in the early era of renal transplantation, lupus pa-
tients were considered unfavourable candidates given an as-
sumed risk of recurrent LN. Since 1975, however, when it was
first suggested that the outcomes of transplant in SLE are
comparable to non-SLE patients [5], there have been reports
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across the globe and in different ethnic populations that have
shown low recurrence rates of LN in kidney transplant recip-
ients [6–9]. Some studies, however, have raised concern re-
garding worse graft and patient survival of SLE patients when
compared to other patient groups (e.g. patients with diabetes),
with unfavourable comparative outcomes, especially for the
recipients of deceased donors [10]. Nonetheless, there is a
relative paucity of data in the literature regarding long-term
outcomes of patients with LN and renal transplantation.
Specifically, although in other patient cohorts undergoing re-
nal transplantation the time spent on dialysis prior to the trans-
plantation has been studied, showing that the longer a patient
spends on dialysis, the worse the overall survival after the
transplantation [11–13], this has not been specifically investi-
gated for lupus patients. As time spent on dialysis before the
transplantation can be a potentially modifiable factor, it is
important to identify whether this is indeed a risk predictor
in the lupus patients and whether there is a Bsafe maximum^
time on dialysis before transplantation. We therefore investi-
gated the long-term survival of patients with LN receiving rTp
and the prognostic effect of the time spent on dialysis pre-
transplant in our cohort of LN patients from two major
London hospitals followed up since 1975.
Methods
This was a retrospective review of all adult SLE patients (aged
> 18 years) from two major London, UK institutions:
University College London Hospital (UCLH) and Royal
Free Hospital (RFH), who developed renal failure and re-
ceived a renal transplant over a 40-year period (1975–2015).
Hospital notes, electronic records and correspondence from
family physicians and physicians in other hospitals were
reviewed. All patients with SLE and related end-stage renal
failure (defined as the need of chronic dialysis therapy or
kidney transplantation due to primarily lupus nephritis) and
who required renal transplantation from January 1975 to
December 2015 were included in this study. In all patients,
6 months of disease quiescence was required prior to trans-
plantation to be included. All patients fulfilled four or more of
the 1982 revised classification criteria for SLE of the
American College of Rheumatology [14] and histological
class of lupus nephritis was defined according to the
International Society of Nephrology/Renal Pathology
Society (ISN/RPS) 2003 classification system [15], applied
retrospectively for the patients who had undergone transplan-
tation prior to 2003.
Published modifiable and non-modifiable parameters pos-
sibly associating with survival were considered, as shown in
Table 1, and recorded for this cohort. This study was a retro-
spective review of a long-term observational registry for
which University College London does not require formal
ethical permission.
The primary endpoint was patient death. Mortality was
assessed from dedicated SLE-transplant clinics and also from
the database at the Office on National Statistics, a dedicated
national registry where all the deaths in UK are recorded.
Statistical analysis
Continuous variables are presented as mean and standard devia-
tion. Categorical variables are presented as numbers and percent-
ages. Cox proportional hazard regression and receiver operating
characteristic (ROC) curves are used to determine potential pre-
dictors. The cumulative survival curves are drawn using the
Kaplan–Meier method. Patient characteristics are summarised
and expressed as mean ± SD (if normally distributed) or other-
wise median and interquartile range (IQR). Comparison between
living and dead patients was undertaken using chi-square, t test
and Mann-Whitney non-parametric t test. A p< 0.05 was con-
sidered significant. IBM SPSS version 22 (IBM Corp., Armonk,
NY, USA) was used for statistical analysis.
Results
A total of 361 patients with lupus nephritis were identi-
fied (155 from RFH and 206 from UCLH). During the 42-
year period of follow-up, 121 progressed to ESRF and 40
of these patients received a renal transplant (eight patients
had been seen in both hospitals and included in the
Table 1 Modifiable and non-modifiable potential risk factors
investigated. APLS, antiphospholipid syndrome, MI myocardial
infarctions, TIA transient ischaemic attack, SLE systemic lupus
erythematosus, LN lupus nephritis, ESRF end-stage renal failure
Modifiable risk factors Non-modifiable risk factors
Time on dialysis Gender
Dialysis type—haemodialysis
vs peritoneal dialysis
Ethnicity
Donor source—cadaveric
vs living
Age of SLE diagnosis
Age of LN
Age of ESRF
Time between SLE and LN
Time between LN and dialysis
Diabetes mellitus (type 1 or 2)
Hypertension
Dyslipidaemia
APLS
Cardiac disease (MI, stroke, TIA)
Decade of renal transplantation
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hospital where they were first seen). The patient charac-
teristics and demographics are presented in Table 2.
Mean age at transplantation was 36 ± 11 years, and 34
(85%) were female. The self-reported ethnic distribution
was similar to that seen in the general lupus cohort of the
two hospitals, with 15 Caucasian (37.5%), 15 Afro–
Caribbean (37.5%), and 10 South Asian (25.0%) under-
going rTp. Five patients were re-transplanted (two pa-
tients received a total of two transplants, and one patient
received a total of three transplants). Follow-up time was
initiated after the first transplant. Two of our patients (5%)
had pre-emptive transplantation and the dialysis time for
them was included as zero.
During a median follow-up of 104 months (IQR 80,145) 8
(20%), patients died (Table 3) and the 5-year survival was
95% which appeared similar across all decades (Table 4).
Three patients (37.5%) died as a consequence of sepsis,
two as a consequence of uraemic complications (25%), two
secondary to malignancy (25%) and one secondary to ischae-
mic heart disease (12.5%). Using univariate Cox regression
time on dialysis and the other potential predictors of survival
were investigated. Univariate analysis only identified time on
dialysis prior to rTp as a predictor of survival with a hazard
ratio of 1.013 for each additional month spent on dialysis
(95% CI = 1.001–1.026, p = 0.03). No other parameter
reached statistical significance as shown in Table 5. In partic-
ular, gender (p = 0.44), ethnicity (p = 0.99), age at SLE diag-
nosis (p = 0.55), age at LN (p = 0.94), age at rTp (p = 0.43),
time between SLE diagnosis and LN (p = 0.37), time between
LN and dialysis (p = 0.54) or indeed any other clinical co-
existing diagnosis; DM (p = 0.56), hypertension (p = 0.32),
dyslipidaemia (p = 0.91) did not affect survival. There was
no difference between the decade the transplant took place
and the outcome (p = 0.71) but this should be interpreted with
caution in view of the low number of rTp undertaken in the
earlier decades. We also compared the length of time on dial-
ysis prior to transplantation in the patients who received the
transplant before or after 2000, which was not statistically
different (p = 0.181). Therefore, these results suggest that the
time on dialysis was the only independent modifiable risk
factor associated with mortality, irrespective of the decade
the transplantation took place.
Nine patients had received mycophenolate mofetil (MMF)/
tacrolimus combination only, with no previous AZA or cyclo-
sporine use, with the other patients having used (azathioprine)
AZA or cyclosporine at any stage. The nine patients who
Table 2 Demographic, clinical and histological features of the patients.
SLE systemic lupus erythematosus, rTp renal transplantation, ESRF end-
stage renal failure, LN lupus nephritis
Demographic characteristics Patient (n = 40)
Gender/female 34
Ethnicity
Caucasian 15
Black 15
Asian 10
Age at SLE diagnosis 21.1 ± 9.2
Age at ESRF 31.6 ± 10.4
Age at rTp 35.5 ± 11.0
Time on dialysis (months) 43 (13–49)
Time of follow-up (months) 104 (80–145)
Type IV LN 18
Donor source/cadaveric 22
Graft failure 9
Table 3 Comparison of clinical
demographics between patients
who survived and who died after
the renal transplantation
Alive (n = 32) Dead (n = 8) p value
Gender/female 26 8 0.32
Age at lupus diagnosis (years) 21 ± 10 22 ± 9 0.77
Age LN 26 ± 8 26 ± 9 0.97
Age at ESRF 31 ± 9 33 ± 15 0.73
Age at renal transplantation (years) 36 ± 11 39 ± 14 0.34
Duration on dialysis prior to renal transplantations (months) 31 (12–39) 84 (68–90) 0.01
Ethnicity
Caucasian 11 (34%) 4 (50%) 0.94
Black 15 (47%) 0
Asian 6 (19%) 4 (50%)
Type of dialysis, HD/PD* 17/9 3/3 0.64
*Eight patients required both PD and HD and therefore not included in the direct comparison between PD and
HD. However, even when compared with PD or HD, there was no evidence that those who required both types of
dialysis have worse outcome (p = 0.89)
LN lupus nephritis, ESRF end-stage renal failure, HD haemodialysis, PD peritoneal dialysis
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received MMF/tacrolimus only had an overall mortality of
11.1% compared to the patients who ever received AZA/
cyclosporine who had a mortality of 22.5%, although this
difference did not reach statistical significance (p = 0.45).
Finally, there was also no difference between the type of dial-
ysis undertaken pre-transplantation and whether it was
haemodialysis or peritoneal dialysis p = 0.64.
Utilising specifically the time spent on dialysis before
the transplantation, a ROC curve was used to calculate the
optimal maximum time spent on dialysis prior to confer-
ring an adverse outcome (Fig. 1) showing that > 24 months
on dialysis had an adverse effect on survival, with an area
under the ROC curve of 0.795, sensitivity of 0.875 and
specificity 0.500 for death.
Utilising this dichotomous value, there was a 2.8-fold
higher risk of mortality in those patients who spent longer
than 24 months on dialysis using Kaplan–Meier curves
(Fig. 2), although there was only a trend towards statisti-
cal significance seen (log rank p = 0.15). This supports the
results from the Cox regression which showed that mor-
tality was increased by 1.3% for every additional month
on dialysis (or 15.6% for every additional year on dialy-
sis) and that most likely if transplantation could be under-
taken by 24 months on dialysis, or even earlier, it could
be of benefit to the patients.
Although not the aim of our study, we also compared
the overall survival of the patients with LN-related ESRF
receiving transplantation vs the ones without transplanta-
tion. In total, 45/81 (56%) died in the non-transplanted
patients compared with 8/40 (20%) of those who received
at least one renal transplant (p = 0.0002). Although the
superiority of renal transplantation in this context is well
recognised [16], this result could have been confounded
by higher burden of comorbidity in the patients not select-
ed for transplantation.
Table 4 Comparison of 5-year mortality according to the decade the
transplant was received
Table comparing survival according to decade of transplantation p value
Dialysis per decade—
5-year survival
Patients
per decade
Mortality
1975–85 2 0/2 0.97
1985–95 3 1/3 (33%)
1995–05 8 2/8 (40%)
2005–15 27 0/24*
*Three patients from the 2005–2015 decade are alive but have not com-
pleted 5 years out from the transplantation and hence are not included in
the table, explaining why it is 0/24 in the last decade
Table 5 Univariate Cox proportional hazard modelling investigating
the association of various parameters and mortality showing that only
risk factor associated with prognosis was time on dialysis, with longer
time on dialysis associated with worse prognosis. SLE systemic lupus
erythematosus, LN lupus nephritis, ESRF end-stage renal failure, rTp
renal transplantation, PD peritoneal dialysis, HD haemodialysis, APLS
antiphospholipid syndrome, MI myocardial infarction, TIA transient
ischaemic attack
Factor p value HR 95% CI
Time on dialysis/per month 0.031 1.013 1.001–1.026
Gender/male 0.442 0.038 0.001–161.3
Ethnicity 0.987 0.995 0.537–1.844
Age at SLE diagnosis 0.552 1.021 0.953–1.094
Age of LN 0.941 1.003 0.920–1.092
Age of ESRF 0.836 1.008 0.935–1.087
Age at rTp 0.431 1.026 0.963–1.092
Dialysis PD (vs HD) 0.764 0.706 0.073–6.862
Time between SLE and LN 0.373 0.996 0.987–1.005
Time between LN and dialysis 0.540 0.999 0.994–1.003
LN duration before dialysis 0.152 1.066 0.977–1.164
Type IV LN 0.398 2.533 0.294–21.82
Dialysis decade 0.712 0.872 0.420–1.807
Diabetes mellitus 0.561 0.038 0.001–2319
Hypertension 0.323 0.329 0.360–2.987
Dyslipidaemia 0.905 0.872 0.092–8.234
APLS 0.508 0.036 0.000–672.6
Cardiac disease (MI, stroke, TIA) 0.873 1.071 0.463–2.476
Donor source (living) 0.353 0.459 0.089–2.372
Graft failure post rTp 0.314 2.073 0.501–8.567
Fig. 1 Receiver operator characteristic (ROC) curve between time on
dialysis and survival. The area under the ROC curve was 0.795.
Patients on dialysis for more than 24 months had a sensitivity of 0.875
and specificity of 0.500 to associate with mortality
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Discussion
Patients with lupus nephritis represent a complex cohort of
patients which should be managed optimally to ensure longer-
term survival. In the present study, we focused on time spent on
dialysis pre-transplantation for renal nephritis as a potentially
modifiable predictor of patient mortality, rather than predictor
of graft failure. We also investigated other potential predictors
of survival both modifiable and non-modifiable. We included
patients going back to the early times of rTp in LN from 1975
and we present data on the longest reported follow-up period
for a dedicated cohort of patients with LN undergoing renal
transplantation. We identified a 5-year survival of 95% which
is in line or better than other published studies [9, 10, 17].
Survival did not appear to differ in relation to the decade the
rTp took place, although this should be considered within the
context of the low numbers of rTp in the very early decades
meaning that the studymight have been underpowered to detect
a small but clinically important difference.
The only variable that appeared to offer any prognostic
association with mortality was time spent on dialysis prior to
the transplant. For every additional month on dialysis, prog-
nosis worsened by 1.3%. If patients exceeded a binary cut-off
of 24 months on dialysis in our cohort, there was a suggestion
that this conferred almost a threefold increase in mortality. No
other factors appeared to affect mortality, as they did not reach
significance in univariate analysis.
The optimal timing of transplantation in patients with LN
reaching ESRF is not known, but this study would support
earlier transplantation if feasible. This is similar to recent work
which found that increased time on dialysis led to increased
graft failure [9, 18]. Indeed, our cohort included two patients
with pre-emptive transplantation and they both remain alive at
22 and 12 years respectively, supporting that the earlier bene-
fits of rTp. Although our research identifies the cut-off of
24 months which could be used to prioritise rTp in LN pa-
tients, further larger and prospective studies are necessary to
identify whether the time relationship to survival up to
24 months is a linear one or whether an even much earlier
and possibly even pre-emptive transplantation should be rec-
ommended and incorporated in current guidelines.
Limitations
Despite combining the data from two large institutions, we
only had 40 patients to analyse, which is however in line or
larger than other similar published studies [9, 17]. Our cohort
also included a mixture of Caucasian, Afro–Caribbean and
South Asian patients and we cannot necessarily extrapolate
our results to patients from other ethnicities. Larger studies
including multiple ethnicities will also allow further compar-
isons. Finally, despite a very long follow-up of 422 patient-
years, only eight patients reached the study endpoint which
may have reduced the identification of the impact of other
potentially predictive variables, for example sex and presence
of antiphospholipid syndrome in particular, which had a wide
confidence interval in our results. In addition, although we
could only undertake univariate analysis due to the small num-
ber of outcomes, this still allows us to accurately identify
individual predictors and trends towards mortality.
Especially as only the time on dialysis was significant, with
patients spending similar times on dialysis throughout the 40-
Fig. 2 Kaplan–Meier estimator
plot between patients who had
less than 24 months of dialysis
(blue line) or more than
24 months (green line),
suggesting a trend of almost
threefold risk of survival in those
spending longer time on dialysis,
HR 2.84 log rank p = 0.15
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year period, we can be confident that this was not influenced
or affected by other parameters. Nonetheless, we propose that
ultimately, multicentre interventional studies are required to
provide adequate power to address this specific question.
Conclusion
In conclusion, in this long-term follow-up study of patients
with SLE and rTp from two large institutions spanning across
four decades, we identified that the only potential modifiable
factor to improve survival was reducing the time on dialysis
prior to transplantation. This finding should be validated in
larger multicentre studies and help identify the optimal timing
of transplantation in LN following ESRF whether on dialysis
or pre-emptively [19].
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